{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:15:52Z","timestamp":1757704552250},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.neuropharm.2004.03.003","type":"journal-article","created":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T09:50:20Z","timestamp":1083405020000},"page":"146-155","source":"Crossref","is-referenced-by-count":13,"title":["Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence"],"prefix":"10.1016","volume":"47","author":[{"given":"J.K.","family":"Callaway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Castillo-Melendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.K.","family":"Krstew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.M.","family":"Beart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Jarrott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2004.03.003_BIB1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1476-5381.1995.tb16635.x","article-title":"Reduction by lifarizine of the neuronal damage induced by cerebral ischemia in rodent","volume":"115","author":"Alps","year":"1995","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB2","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1523\/JNEUROSCI.06-07-02064.1986","article-title":"3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin","volume":"6","author":"Brown","year":"1986","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/sj.bjp.0704018","article-title":"Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis","volume":"132","author":"Callaway","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB4","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1161\/01.STR.30.12.2704","article-title":"Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats","volume":"30","author":"Callaway","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0165-0270(00)00278-8","article-title":"A novel, rapid, computerised method for quantitation of neuronal damage in a rat model of stroke","volume":"102","author":"Callaway","year":"2000","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0028-3908(03)00068-6","article-title":"AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of consious rats after endothelin-1-induced middle cerebral artery occlusion","volume":"44","author":"Callaway","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01345257","article-title":"The importance of voltage-dependent sodium channels in cerebral ischaemia","volume":"14","author":"Carter","year":"1998","journal-title":"Amino Acids"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB8","series-title":"Excitatory Amino Acids\u2014Clinical Results with Antagonists","first-page":"57","article-title":"Ifenprodil and eliprodil: neuroprotective NMDA receptor antagonists and calcium channel blockers","author":"Carter","year":"1997"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(00)81133-2","article-title":"From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels","volume":"26","author":"Catterall","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB10","doi-asserted-by":"crossref","first-page":"8922","DOI":"10.1016\/S0021-9258(19)52487-5","article-title":"Binding of batrachotoxinin A 20-\u03b1-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles","volume":"256","author":"Catterall","year":"1981","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0920-1211(92)90065-2","article-title":"An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels","volume":"13","author":"Cheung","year":"1992","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1097-4547(19980401)52:1<69::AID-JNR7>3.0.CO;2-I","article-title":"Kainate-induced apoptosis correlates with c-Jun activation in cultured cerebellar granule cells","volume":"52","author":"Cheung","year":"1998","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB13","first-page":"2712","article-title":"Editorial comment. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats","volume":"30","author":"Clemens","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB14","first-page":"350","article-title":"Batrachotoxin-induced depolarization and [3H]batrachotoxinin-A 20\u03b1-benzoate binding in a vesicular preparation from guinea pig cerebral cortex","volume":"23","author":"Creveling","year":"1983","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB15","first-page":"748","article-title":"Lubeluzole protects sensory motor function and reduces infarct size in a photochemical stroke model in rats","volume":"279","author":"De Ryck","year":"1996","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-2999(99)00280-0","article-title":"Drug development for stroke: importance of protecting cerebral white matter","volume":"375","author":"Dewar","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB17","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1212\/WNL.47.4.884","article-title":"Evolving stroke and the ischemic penumbra","volume":"47","author":"Fisher","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB18","first-page":"854","article-title":"Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion","volume":"269","author":"Graham","year":"1994","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB19","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/jm020875j","article-title":"Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use dependent sodium channel blockers for the treatment of stroke","volume":"45","author":"Grauert","year":"2002","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB20","first-page":"354","article-title":"AM-36 reduces cerebral white matter damage in the endothelin-1 model of stroke in conscious rats","volume":"14","author":"Gresle","year":"2003"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0006-8993(01)02195-3","article-title":"The use-dependent sodium channel blocker mexiletine is neuroprotective against global ischemic injury","volume":"898","author":"Hewitt","year":"2001","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB22","unstructured":"Jarrott, B., Beart, P., Jackson, W., Kenche, V., Robertson, A., Collis, M., 1997. Arylalkylpiperazine compounds as antioxidants. Patent Cooperation Treaty No. WO97\/43259, Australia."},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1098-2299(199903\/04)46:3\/4<261::AID-DDR11>3.0.CO;2-Q","article-title":"Development of a novel arylalkylpiperazine compound (AM-36) as a hybrid neuroprotective drug","volume":"46","author":"Jarrott","year":"1999","journal-title":"Drug Development Research"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0197-0186(97)00050-8","article-title":"In vivo microdialysis reveals facilitatory metabotropic glutamate receptors regulating excitatory amino acid release in rat nucleus tractus solitarius","volume":"32","author":"Jones","year":"1998","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB25","first-page":"199","article-title":"Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows","volume":"4","author":"Kuroda","year":"1997","journal-title":"Clinical Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0306-4522(94)90083-3","article-title":"l-glutamate as a neurotransmitter at baroreceptor afferents: evidence from in vivo microdialysis","volume":"58","author":"Lawrence","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1471-4159.1992.tb09289.x","article-title":"Terminal autoreceptor control of 5-hydroxytryptamine release as measured by in vivo microdialysis in the conscious guinea pig","volume":"58","author":"Lawrence","year":"1992","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/01.STR.24.7.1063","article-title":"BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage","volume":"24","author":"Leach","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00001756-200303030-00044","article-title":"Sipatrigine and oligodendrocyte and axonal pathology following transient focal cerebral ischemia in the rat","volume":"14","author":"McCraken","year":"2003","journal-title":"NeuroReport"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0028-3908(99)00201-4","article-title":"Inhibition of recombinant low-voltage-activated Ca2+ channels by the neuroprotective agent BW619C89 (sipatrigine)","volume":"39","author":"McNaughton","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB31","series-title":"RADLIG (Version 4)","author":"McPherson","year":"1994"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(92)91254-C","article-title":"Reduction of glutamate release and protection against ischemic brain damage by BW 1003C87","volume":"593","author":"Meldrum","year":"1992","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB33","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1523\/JNEUROSCI.16-23-07487.1996","article-title":"Metabolic and genetic analyses of apoptosis in potassium\/serum-deprived rat cerebellar granule cells","volume":"16","author":"Miller","year":"1996","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/13543784.11.10.1407","article-title":"Antioxidants as treatment for neurodegenerative disorders","volume":"11","author":"Moosmann","year":"2002","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"Journal of Immunological Methods"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000016103","article-title":"Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke","volume":"10","author":"Muir","year":"2000","journal-title":"Cerebrovascular Diseases"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB37","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/01.STR.28.3.652","article-title":"Pathogenesis of leukoaraiosis: a review","volume":"28","author":"Pantoni","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1071\/CH01193","article-title":"Cyclic voltammetry as an indicator of antioxidant activity","volume":"55","author":"Papanikos","year":"2002","journal-title":"Australian Journal of Chemistry"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB39","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB40","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/01.STR.30.5.956","article-title":"Axonal injury in the internal capsule correlates with motor impairment after stroke","volume":"30","author":"Pendleberry","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0165-0173(99)00025-9","article-title":"White matter ischemia","volume":"31","author":"Petty","year":"1999","journal-title":"Brain Research Reviews"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB42","first-page":"245","article-title":"Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole","volume":"94","author":"Schwartz","year":"2001","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/jcbfm.1993.108","article-title":"Perivascular microapplication of endothelin-1: a new model of focal cerebral ischaemia in the rat","volume":"13","author":"Sharkey","year":"1993","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB44","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0306-4522(96)00530-1","article-title":"Long-term beneficial effects of BW619C89 on neurological deficit, cognitive deficit and brain damage after middle cerebral artery occlusion in the rat","volume":"77","author":"Smith","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00001756-200207020-00019","article-title":"Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons","volume":"13","author":"Spadoni","year":"2002","journal-title":"NeuroReport"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000108016","article-title":"The effects of lifarizine in acute cerebral infarction: a pilot safety study","volume":"6","author":"Squire","year":"1996","journal-title":"Cerebrovascular Diseases"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0306-4522(97)00230-3","article-title":"Mechanisms of calcium and sodium fluxes in anoxic myelinated central nervous system axons","volume":"82","author":"Stys","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0165-6147(00)89060-4","article-title":"Sodium channels as targets for neuroprotective drugs","volume":"16","author":"Taylor","year":"1995","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB49","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ana.410150608","article-title":"Focal cerebral ischemia in the rat: topography of hemodynamic and histopathological changes","volume":"15","author":"Tyson","year":"1984","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2004.03.003_BIB50","first-page":"21","article-title":"Pharacological modulation of voltage-gated Na+ channels: a rational and effective strategy against ischaemic brain damage","volume":"48","author":"Urenjak","year":"1996","journal-title":"Pharmacological Reviews"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T06:14:58Z","timestamp":1623910498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390804000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0028390804000693"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2004.03.003","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}